A Randomized Controlled Trial Of Dehydroepiandrosterone In Postmenopausal Women With Fibromyalgia

Effect None
Values By the end of the study, there were no changes in PGWBI scores in either group. PGWBI scores (range 0-110). DHEA group - baseline: 59.2 (5.7) 3 months: 59.6 (4.8) placebo group - baseline: 58.5 (4.7) 3 months: 58.9 (5) p value = 0.45
Trial Design Randomized trial
Trial Length 1-6 months
Number of Subjects 52
Sex Female
Age Range 45-64, 65+
Notes for this study:
This 3-month randomized double-blind study had 52 females with fibromyalgia consume either 50 mg of DHEA or a placebo daily. All the participants began the study with a one-month run-in period, after which, they were randomized to either the DHEA or placebo group. After the 3 month intervention period, there was a one-month wash-out period followed by another 3-month intervention after crossing over. The primary outcome was quality of life measured by the Psychological General Well Being Index (PGWBI). Secondary outcomes were pain measured by Regional Pain Score (RPS), the number of pain medications taken during the last week, Hospital Anxiety and Depression Scale (HAD), functional impairment measured by the Fibromyalgia Health Assessment Questionnaire (FHAQ), cognitive function as measured by the Cognitive Difficulties Scale (CDS), and sexual satisfaction and libido as measured by the McCoy Female Sexuality Questionnaire (McCoy FSQ).

By the end of the study, there were no statistically significant changes in any of the outcomes in either groups.